Sobre fluoroquinolonas

En el ACP Internist Weekly del 24/05/16 encontramos este artículo que creo que vale la pena compartir

Updated warning issued on risks of fluoroquinolones

The side effects of fluoroquinolones generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections, according to a new FDA warning.
The agency is having an updated boxed warning added to the drugs' labels, based on a safety review showing that systemic fluoroquinolones are associated with disabling and potentially permanent serious side effects that can occur together and can involve the tendons, muscles, joints, nerves, and central nervous system.

Fluoroquinolone use for sinusitis, bronchitis, and uncomplicated urinary tract infections should be reserved for patients who do not have alternative treatment options, according to an FDA safety communication. If a patient reports serious side effects from a systemic fluoroquinolone, the drug should be stopped immediately and the patient should be switched to a nonfluoroquinolone antibacterial drug to complete the treatment course, the FDA said. The agency is continuing to investigate safety issues with fluoroquinolones and will update the public with additional information if it becomes available.